Expert Perspectives on Extended Follow-Up Data from ALPINE

Opinion
Video

Chaitra S. Ujjani, MD examines extended follow-up data from the ALPINE trial, emphasizing noteworthy findings from the sensitivity and safety analyses recently presented at ASH 2023.

This is a video synopsis/summary of a News Network involving Richard Furman, MD, and Chaitra S. Ujjani, MD.

Ujjani discusses Bruton tyrosine kinase (BTK) inhibitor selection in the relapse/refractory setting, focusing on the ALPINE study comparing zanubrutinib and ibrutinib. Results reveal a significant progression-free survival benefit with zanubrutinib (66%) over ibrutinib (50%) at 3 years, particularly in high-risk patients with TP53 mutations. Unexpectedly, sensitivity analyses show a progression-free survival difference even when patients stay on either inhibitor.

Regarding safety, zanubrutinib exhibits fewer cardiac adverse events, especially atrial fibrillation, making it favorable for older patients with cardiac comorbidities. The ease of zanubrutinib on patients, with minimal need for dose modifications, distinguishes its safety profile. Ujjani speculates on factors like BTK inhibition selection contributing to the unexpected outcome.

In summary, the ALPINE study highlights zanubrutinib’s efficacy and safety advantages over ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia, impacting treatment decisions in this setting.

This summary was AI-generated and reviewed by OncLive® editorial staff.

Related Videos
Video 18 - "Reflecting on Differentiated Thyroid Cancer: Final Insights"
Video 17 - "Phase 2 ATLEP Trial Results"
Video  10 -"Real-World Evidence on Second-Line Therapy Selection and Outcomes"
Video  9 - "Additional Second-Line Treatments for HCC"
Video 16 - "Neoadjuvant Approach in RAI-R-DTC"
Video 15 - "Addressing Unmet Needs and Challenges in RAI-R-DTC Treatment"
Video 8 - "The Evolving Landscape of Second-Line Therapies in HCC Management"
Video 7 - "Comorbidity Considerations for HCC Treatment"
Video 8 - "Future Outlook for RET Fusion-Targeted Therapies"
Video 7 - "Impact and Positioning of Tumor Agnostic Approvals"
Related Content